What is the efficacy of chimeric antigen receptor (CAR) T-cell therapy for follicular lymphoma?

Updated: Dec 17, 2020
  • Author: Sameh Gaballa, MD, MS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Currently, no FDA-approved CAR T products are available for patients with follicular lymphoma. Earlier studies included small numbers of follicular lymphoma patients who underwent CAR T with CTL019. [23]  In the 14 follicular lymphoma patients who received CTL019, the ORR was 89%, with 71% of patients achieving a CR.

Most recently, the interim analysis from the Zuma-5 study were presented at ASCO 2020 for patients with R/R indolent lymphomas (80 follicular lymphoma, 14 marginal zone lymphoma) in whom at least 2 prior lines of therapy had failed. All patients received a single infusion of axicabtagene ciloleucel. Of the 87 evaluable patients, the ORR was 94%, with 79% achieving CR. [24] After a median follow-up of 15.3 months, the estimated median progression-free survival (PFS) was 23.5 months (95% CI, 22.8%–not estimable) in all patients, and 68% of patients with follicular lymphoma had an ongoing response. This compares very favorably with the 1-year PFS currently achieved with PI3K inhibitors. [25]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!